NBY Novabay Pharmaceuticals Inc.
- 0 P/E
- 19.36 P/S
- 4.23 P/B
- -0.335 EPS
- -2,345.19% Cash ROIC
- 3.60 Cash Ratio
- 0.00 / N/A % Dividend
- 312,563.00 Avg. Vol.
- 38.18M Shares
- 39.1M Market Cap.
NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
Business Wire (press release) - 2 hours ago
Seeking Alpha (registration) - Aug 20, 2014
Yahoo Finance UK - Aug 25, 2014
Wall Street Journal - Jul 31, 2014
Tech News - Aug 26, 2014
Techsonian (press release) - Aug 25, 2014
eFinance Hub - Aug 21, 2014
Crazy Joys - Aug 18, 2014
Market News Call - Aug 19, 2014
WallStreet Scope - Aug 25, 2014